Lipocine Company Profile (NASDAQ:LPCN)

About Lipocine (NASDAQ:LPCN)

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:LPCN
  • CUSIP: N/A
  • Web: www.lipocine.com
Capitalization:
  • Market Cap: $70.11 million
  • Outstanding Shares: 19,261,000
Average Prices:
  • 50 Day Moving Avg: $3.83
  • 200 Day Moving Avg: $3.77
  • 52 Week Range: $2.51 - $9.59
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.99
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.29 per share
  • Price / Book: 2.82
Profitability:
  • EBIDTA: ($16,260,000.00)
  • Return on Equity: -59.35%
  • Return on Assets: -55.10%
Debt:
  • Current Ratio: 18.73%
  • Quick Ratio: 18.73%
Misc:
  • Average Volume: 157,092 shs.
  • Beta: 1.88
  • Short Ratio: 9.48
 

Frequently Asked Questions for Lipocine (NASDAQ:LPCN)

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine Inc (NASDAQ:LPCN) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.04. View Lipocine's Earnings History.

Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?

3 analysts have issued 12 month target prices for Lipocine's shares. Their forecasts range from $10.00 to $30.00. On average, they expect Lipocine's stock price to reach $21.67 in the next year. View Analyst Ratings for Lipocine.

Are investors shorting Lipocine?

Lipocine saw a increase in short interest in April. As of April 13th, there was short interest totalling 1,774,743 shares, an increase of 6.2% from the March 31st total of 1,671,769 shares. Based on an average daily volume of 94,462 shares, the short-interest ratio is currently 18.8 days.

Who are some of Lipocine's key competitors?

Who owns Lipocine stock?

Lipocine's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Royce & Associates LP (6.34%), VHCP Management II LLC (2.26%), Vanguard Group Inc. (2.10%), Dimensional Fund Advisors LP (1.39%), JPMorgan Chase & Co. (1.04%) and Ameriprise Financial Inc. (0.71%). Company insiders that own Lipocine stock include John W Higuchi and Mahesh V Patel. View Institutional Ownership Trends for Lipocine.

Who sold Lipocine stock? Who is selling Lipocine stock?

Lipocine's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., TIAA CREF Investment Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Lipocine.

Who bought Lipocine stock? Who is buying Lipocine stock?

Lipocine's stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Vanguard Group Inc., Parametric Portfolio Associates LLC, KCG Holdings Inc., Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi and Mahesh V Patel. View Insider Buying and Selling for Lipocine.

How do I buy Lipocine stock?

Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Lipocine stock cost?

One share of Lipocine stock can currently be purchased for approximately $3.64.

Analyst Ratings

Consensus Ratings for Lipocine (NASDAQ:LPCN) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.67 (495.24% upside)

Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/26/2017HC WainwrightReiterated RatingBuy$25.00LowView Rating Details
4/24/2017Canaccord GenuitySet Price TargetBuy$10.00HighView Rating Details
12/6/2016Roth CapitalSet Price TargetBuy$30.00N/AView Rating Details
7/17/2015Evercore ISIInitiated CoverageBuy$18.00N/AView Rating Details
7/16/2015Evercore Partners Inc.Initiated CoverageBuy$18.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Lipocine (NASDAQ:LPCN)
Earnings by Quarter for Lipocine (NASDAQ:LPCN)
Earnings History by Quarter for Lipocine (NASDAQ:LPCN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.30)($0.26)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.28)($0.16)ViewN/AView Earnings Details
8/9/2016Q2($0.37)($0.32)ViewN/AView Earnings Details
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details
3/10/2016Q4 2015($0.29)($0.25)ViewN/AView Earnings Details
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.20)($0.26)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.35)($0.23)ViewN/AView Earnings Details
3/11/2015Q4 2014($0.35)($0.32)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.58)($0.32)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.42)($0.55)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.35)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lipocine (NASDAQ:LPCN)
2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.20)($0.20)($0.20)
Q2 20172($0.33)($0.31)($0.32)
Q3 20172($0.28)($0.12)($0.20)
Q4 20172($0.30)($0.15)($0.23)
Q1 20181$0.82$0.82$0.82
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Lipocine (NASDAQ:LPCN)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 45.02%
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00View SEC Filing  
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00View SEC Filing  
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Lipocine (NASDAQ:LPCN)
Latest Headlines for Lipocine (NASDAQ:LPCN)
Source:
DateHeadline
finance.yahoo.com logoLPCN 1021 Readout in June; 1Q:17 R&D Costs Lower
finance.yahoo.com - May 16 at 6:11 PM
americanbankingnews.com logoLipocine Inc Expected to Earn FY2017 Earnings of ($1.17) Per Share (LPCN)
www.americanbankingnews.com - May 15 at 8:43 AM
americanbankingnews.com logoLipocine Inc (LPCN) Expected to Earn Q2 2017 Earnings of ($0.33) Per Share
www.americanbankingnews.com - May 12 at 10:24 AM
businesswire.com logoRobbins Arroyo LLP: Lipocine Inc. (LPCN) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - May 11 at 11:52 PM
finance.yahoo.com logoRobbins Arroyo LLP: Lipocine Inc. (LPCN) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - May 9 at 6:05 PM
americanbankingnews.com logoLipocine Inc (LPCN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 12:52 PM
globenewswire.com logoLipocine Announces Financial and Operational Results for the First Quarter 2017 - GlobeNewswire (press release)
globenewswire.com - May 8 at 5:57 PM
finance.yahoo.com logoLipocine Announces Financial and Operational Results for the First Quarter 2017
finance.yahoo.com - May 8 at 10:58 AM
marketbeat.com logoLipocine reports 1Q loss
marketbeat.com - May 8 at 8:15 AM
americanbankingnews.com logoShort Interest in Lipocine Inc (LPCN) Grows By 6.2%
www.americanbankingnews.com - May 5 at 12:24 PM
americanbankingnews.com logo Analysts Anticipate Lipocine Inc (LPCN) to Post -$0.20 Earnings Per Share
www.americanbankingnews.com - May 5 at 12:16 PM
americanbankingnews.com logoLipocine (LPCN) Receives Coverage Optimism Rating of 0.31
www.americanbankingnews.com - May 3 at 2:36 PM
americanbankingnews.com logoLipocine (LPCN) Given News Impact Rating of -0.25
www.americanbankingnews.com - April 30 at 7:49 AM
americanbankingnews.com logoLipocine (LPCN) Given Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 28 at 12:22 AM
americanbankingnews.com logoLipocine's (LPCN) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 26 at 10:12 PM
americanbankingnews.com logoCanaccord Genuity Analysts Give Lipocine Inc (LPCN) a $10.00 Price Target
www.americanbankingnews.com - April 25 at 4:16 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Somewhat Likely to Affect Lipocine (LPCN) Stock Price
www.americanbankingnews.com - April 24 at 9:34 PM
streetinsider.com logoLipocine (LPCN) Says Enrollment in LPCN 1021 Fixed Dose Trials Has Been Completed
www.streetinsider.com - April 24 at 4:58 PM
finance.yahoo.com logoLipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials
finance.yahoo.com - April 24 at 4:58 PM
americanbankingnews.com logoLipocine (LPCN) Receiving Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 18 at 10:00 AM
americanbankingnews.com logoLipocine (LPCN) Earns Daily Coverage Optimism Rating of -0.12
www.americanbankingnews.com - April 15 at 12:11 PM
americanbankingnews.com logoLipocine Inc (LPCN) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - April 14 at 1:16 PM
globenewswire.com logoLipocine to Present at 16th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 28 at 10:57 PM
globenewswire.com logoLipocine to Present at 27th Annual Oppenheimer Conference - GlobeNewswire (press release)
globenewswire.com - March 15 at 11:37 PM
finance.yahoo.com logoLipocine to Present at 27th Annual Oppenheimer Conference
finance.yahoo.com - March 14 at 11:21 AM
streetinsider.com logoH.C. Wainwright Remains bullish on Lipocine (LPCN) Following 4Q
www.streetinsider.com - March 13 at 6:05 PM
us.rd.yahoo.com logoLPCN: Conserving Cash to Fund Underway DV and DF Studies
us.rd.yahoo.com - March 13 at 6:05 PM
americanbankingnews.com logoLipocine Inc (LPCN) Given a $25.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 13 at 4:28 PM
streetinsider.com logoH.C. Wainwright Remains bullish on Lipocine (LPCN) Following 4Q - StreetInsider.com
www.streetinsider.com - March 13 at 10:32 AM
finance.yahoo.com logoLIPOCINE INC. Financials
finance.yahoo.com - March 10 at 7:34 PM
finance.yahoo.com logoLipocine Announces Financial and Operational Results for the Full Year of 2016
finance.yahoo.com - March 6 at 5:52 PM
biz.yahoo.com logoLIPOCINE INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 6 at 5:52 PM
biz.yahoo.com logoLIPOCINE INC. Files SEC form 8-K, Other Events
biz.yahoo.com - March 6 at 5:52 PM
globenewswire.com logoLipocine to Present at 29th Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:41 AM
finance.yahoo.com logoLipocine to Present at 29th Annual ROTH Conference
finance.yahoo.com - March 6 at 8:41 AM
biz.yahoo.com logoLIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - February 25 at 6:01 PM
finance.yahoo.com logoLipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer - Yahoo Finance
finance.yahoo.com - February 17 at 1:25 PM
biz.yahoo.com logoLIPOCINE INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 8 at 7:07 PM
streetinsider.com logoForm 4 Lipocine Inc. For: Jan 26 Filed by: BROWN MORGAN R
www.streetinsider.com - January 31 at 5:06 AM
nasdaq.com logoLipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of ... - Nasdaq
www.nasdaq.com - January 11 at 5:18 AM
streetinsider.com logoLipocine (LPCN) Receives Additional FDA Guidance on LPCN 1107 Pivotal Phase 3 Study Design
www.streetinsider.com - January 9 at 7:06 PM
us.rd.yahoo.com logoLipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
us.rd.yahoo.com - January 9 at 7:06 PM
reuters.com logoBRIEF-Lipocine Inc plans to initiate a dosing flexibility study
www.reuters.com - January 6 at 6:59 PM
finance.yahoo.com logoLPCN: Early Start to Tlando Validation Trial
finance.yahoo.com - January 6 at 6:59 PM
streetinsider.com logoForm 8-K Lipocine Inc. For: Jan 05 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - January 6 at 5:48 AM
streetinsider.com logoLipocine (LPCN) to Initiates LPCN 1021 Dosing Flexibility Study
www.streetinsider.com - January 5 at 7:45 PM
us.rd.yahoo.com logoLipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate
us.rd.yahoo.com - January 5 at 7:45 PM
us.rd.yahoo.com logo8:05 am Lipocine to initiate a dosing flexibility study in addition to its previously announced dosing validation study for LPCN 1021; expects top-line results in 2Q17
us.rd.yahoo.com - January 5 at 7:45 PM

Social

Chart

Lipocine (LPCN) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff